Top Suppliers:I want be here


607742-69-8

607742-69-8 structure
607742-69-8 structure
  • Name: SB742457
  • Chemical Name: 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline
  • CAS Number: 607742-69-8
  • Molecular Formula: C19H19N3O2S
  • Molecular Weight: 353.438
  • Catalog: Biochemical Inhibitor Neuronal Signaling 5-HT Receptor Antagonist
  • Create Date: 2018-08-03 18:29:20
  • Modify Date: 2024-01-02 20:51:05
  • SB742457 is a highly selective 5-HT6 receptor antagonist with pKi of 9.63; exhibits >100-fold selectivity over other receptors.IC50 Value: 9.63 (pKi)Target: 5-HT6 ReceptorSB-742457, a 5-HT6 receptor antagonist, which extends into Alzheimer disease (AD) sufferers further highlights the therapeutic promise of this mechanistic approach. Alzheimer's disease is a devastating neurological condition characterized by a progressive decline in cognitive performance accompanied by behavioral and psychological syndromes, such as depression and psychosis. With the subsequent development of selective 5-HT6 receptor antagonists, preclinical studies in rodents and primates have elucidated the function of this receptor subtype in more detail. It is increasingly clear that blockade of 5-HT6 receptors leads to an improvement of cognitive performance in a wide variety of learning and memory paradigms and also results in anxiolytic and antidepressant-like activity. SB-742457 is generally safe and well tolerated and may be efficacious in Alzheimer disease.

Name 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline
Synonyms SB-742,457
Quinoline,3-(phenylsulfonyl)-8-(1-piperazinyl)
RVT-101
GSK-742457
3-(phenylsulfonyl)-8-(piperazin-1-yl)quinoline
Intepirdine
Quinoline, 3-(phenylsulfonyl)-8-(1-piperazinyl)-
UNII-2IOB2M82HY
SB-742457
3-(Phenylsulfonyl)-8-(1-piperazinyl)quinoline
SB742457
Description SB742457 is a highly selective 5-HT6 receptor antagonist with pKi of 9.63; exhibits >100-fold selectivity over other receptors.IC50 Value: 9.63 (pKi)Target: 5-HT6 ReceptorSB-742457, a 5-HT6 receptor antagonist, which extends into Alzheimer disease (AD) sufferers further highlights the therapeutic promise of this mechanistic approach. Alzheimer's disease is a devastating neurological condition characterized by a progressive decline in cognitive performance accompanied by behavioral and psychological syndromes, such as depression and psychosis. With the subsequent development of selective 5-HT6 receptor antagonists, preclinical studies in rodents and primates have elucidated the function of this receptor subtype in more detail. It is increasingly clear that blockade of 5-HT6 receptors leads to an improvement of cognitive performance in a wide variety of learning and memory paradigms and also results in anxiolytic and antidepressant-like activity. SB-742457 is generally safe and well tolerated and may be efficacious in Alzheimer disease.
Related Catalog
References

[1]. Callaghan CK, Hok V, Della-Chiesa A, et al. Age-related declines in delayed non-match-to-sample performance (DNMS) are reversed by the novel 5HT6 receptor antagonist SB742457. Neuropharmacology. 2012 Oct;63(5):890-7.

[2]. Codony X, Vela JM, Ramírez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol. 2011 Feb;11(1):94-100.

[3]. Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry. 2011 May;26(5):536-44.

[4]. Maher-Edwards G, Zvartau-Hind M, Hunter AJ, et al. Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr Alzheimer Res. 2010 Aug;7(5):374-85.

[5]. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics. 2008 Jul;5(3):458-69.

[6]. SB-742457

Density 1.3±0.1 g/cm3
Boiling Point 608.3±45.0 °C at 760 mmHg
Molecular Formula C19H19N3O2S
Molecular Weight 353.438
Flash Point 321.7±28.7 °C
Exact Mass 353.119812
PSA 70.68000
LogP 2.10
Vapour Pressure 0.0±1.7 mmHg at 25°C
Index of Refraction 1.649
Storage condition -20℃

~73%

607742-69-8 structure

607742-69-8

Literature: GLAXO GROUP LIMITED Patent: WO2005/26125 A1, 2005 ; Location in patent: Page/Page column 21-22 ; WO 2005/026125 A1

~84%

607742-69-8 structure

607742-69-8

Literature: GLAXO GROUP LIMITED Patent: WO2007/39238 A1, 2007 ; Location in patent: Page/Page column 14-16 ;

~69%

607742-69-8 structure

607742-69-8

Literature: Emmett, Edward J.; Hayter, Barry R.; Willis, Michael C. Angewandte Chemie - International Edition, 2013 , vol. 52, # 48 p. 12679 - 12683 Angew. Chem., 2013 , vol. 125, # 48 p. 12911 - 12915,5

~%

607742-69-8 structure

607742-69-8

Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890

~%

607742-69-8 structure

607742-69-8

Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890

~%

607742-69-8 structure

607742-69-8

Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890

~%

607742-69-8 structure

607742-69-8

Literature: Journal of Medicinal Chemistry, , vol. 57, # 9 p. 3884 - 3890